ANI Pharma (ANIP) Misses Q2 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ANI Pharmaceuticals Reports Second Quarter 2020 Results
August 6, 2020 6:50 AM EDT- Second quarter 2020 net revenues of $48.5 million -
- Nikhil Lalwani named President and CEO, effective September 8, 2020
- Pharmaceutical industry executives, Jeanne Thoma and Tony Pera, join Board of Directors -
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020.
Business and Recent Highlights:
Completed comprehensive gap assessment on lead product, Cortrophin®... More